Rising resistance of HIV to non-nucleoside reverse transcriptase inhibitors (NNRTIs) threatens the success of the global scale-up of antiretroviral therapy (ART). The switch to dolutegravir (DTG)-based regimens could reduce this threat due to DTG’s high genetic barrier to resistance. Dr Nyuma Mbewe (University of Zambia, Lusaka, Zambia) joins touchINFECTIOUSDISEASES to discuss these challenges associated with ART comprising NNRTIs and the advantages of dolutegravir over them.
The presentation entitled ‘Incident tuberculosis as a risk factor for viral non-suppression 48 weeks among patients switched to dolutegravir based therapy with recycled nucleoside reverse transcriptase inhibitors in Lusaka, Zambia’ was presented at the International AIDS Society (IAS) 29 July – 2 August, 2022.
Questions:
- What have been the challenges associated with antiretroviral treatment (ART) comprising a non-nucleoside reverse-transcriptase inhibitors (NNRTI) in resource-limited settings? (00:26)
- What is dolutegravir and what are its advantages over NNRTIs? (01:17)
Disclosures: Nyuma Mbewe has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
